CRISPR/Cas9-based genome editing in the era of CAR T cell immunotherapy

• Main Authors: January Salas-Mckee (Author), Weimin Kong (Author), Whitney L. Gladney (Author), Julie K. Jadlowsky (Author), Gabriela Plesa (Author), Megan M. Davis (Author), Joseph A. Fraietta (Author)
• Format: Book
• Published: Taylor & Francis Group, 2019-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The advent of engineered T cells as a form of immunotherapy marks the beginning of a new era in medicine, providing a transformative way to combat complex diseases such as cancer. Following FDA approval of CAR T cells directed against the CD19 protein for the treatment of acute lymphoblastic leukemi...